Rheumatology

Real-World Data Show Mixed Results for CT-P13 Worldwide

October 15th 2018

By Kelly Davio

During the American College of Rheumatology 2018 annual meeting, which will be held from October 19-24 in Chicago, Illinois, a variety of researchers will present on real-world data concerning biosimilar infliximab CT-P13.

European Analysis Finds Infliximab to Be Most Cost-Effective Biologic for RA

October 11th 2018

By The Center for Biosimilars Staff

Article

The paper reports findings from a study that used retrospective data from a single center in Poland from 2009 to 2014. Records from a total of 104 patients, each of whom received infliximab, etanercept, or adalimumab under the National Health Fund, were assessed.

NHS Releases Patient Education Materials in Preparation for Biosimilar Adalimumab

September 25th 2018

By Samantha DiGrande

Article

The National Health Service’s (NHS) Specialist Pharmacy Service released resources for clinicians to use with patients in the discussions around switching from the reference Humira to a biosimilar.

Switching to Biosimilars in Rheumatological Indications Is Safe, Review Says

September 25th 2018

By Kelly Davio

Article

The latest review seeking to reassure clinicians about the safety of switching their patients to biosimilars focuses on rheumatology indications.

Researchers Present on Making AS Treatment More Affordable and More Effective

September 20th 2018

By Kelly Davio

Article

Treating ankylosing spondylitis (AS) is costly, even in high-income nations. In lower-income countries, patients may face serious challenges in accessing high-cost drugs, like anti–tumor necrosis factor agents, even when biosimilars are available.

Effective Switches to Biosimilars Feature in APLAR Research

September 19th 2018

By Kelly Davio

Article

During the 20th Asia Pacific League of Associations for Rheumatology (APLAR) Congress, held September 6 to 9 in Kaohsiung, Taiwan, researchers presented on real-world experience with switching to biosimilars in treating rheumatic diseases.

More Evidence of Low Rates of Adherence and Persistence for Biologics for Inflammatory Diseases

September 13th 2018

By Jackie Syrop

Article

Adherence and persistence rates for biologic drugs are still low in the United States, leading to suboptimal patient outcomes and putting a substantial burden on the healthcare system.

Celltrion Asks NHS to Start Biologics Earlier in Patients With RA

September 5th 2018

By The Center for Biosimilars Staff

Article

Currently, UK eligibility criteria for starting biologics in patients with rheumatoid arthritis (RA) set a threshold of a disease activity score in a count of 28 joints of 5.1 or higher—the threshold for severe disease—on at least 2 occasions measured 1 month apart.

Celltrion Completes Phase 3 Trial for Subcutaneous Inflectra

September 4th 2018

By The Center for Biosimilars Staff

Article

Celltrion announced last week that it has completed its phase 3 clinical trial for subcutaneous biosimilar infliximab (CT-P13, sold in the United States as Inflectra and in other territories as Remsima), and that it will now prepare a marketing authorization application for submission to the European Medicines Agency.

Review Suggests That Rheumatologists, Patients Need More Data on Switching to Etanercept Biosimilars

September 2nd 2018

By The Center for Biosimilars Staff

Article

Regulators licensed the 3 etanercept biosimilars discussed for all of the indications of the reference drug on the basis of the extrapolation of indications, a practice that the authors say rheumatologists may find “anomalous and a source of debate.”